UPB · Upstream Bio, Inc.
$2.74
-8.36% last session
End-of-day data · close of 2026-10-23
Market cap
<$1M
Enterprise value
<$1M
Trailing P/E
—
Forward P/E
-1.0
Dividend yield
0.0%
Beta
1.39
Avg volume
1M
Employees
0K
Daily Change %
-8.36%
5 Days Change
-2.14%
10 Days Change
-19.88%
30 Days Change
-47.00%
60 Days Change
-61.84%
Month to Day Change
-45.63%
Year to Day Change
-89.91%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — UPB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-02
Latest call per bank · past 12 months
JP Morgan
Neutral$9.00
+228.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-02 | HC Wainwright & Co. | Reiterates | Buy | $36.00 |
| 2026-08-14 | JP Morgan | Maintains | Neutral | $8.00 → $9.00 |
| 2026-08-12 | Truist Securities | Maintains | Buy | $43.00 → $25.00 |
| 2026-06-12 | JP Morgan | Downgrade | Overweight → Neutral | $35.00 → $8.00 |
| 2026-06-03 | HC Wainwright & Co. | Initiates | Buy | $0.00 → $36.00 |
| 2026-05-14 | Mizuho | Maintains | Outperform | $51.00 → $50.00 |
| 2026-03-27 | Evercore ISI Group | Downgrade | Outperform → In-Line | $40.00 → $15.00 |
| 2025-12-18 | Mizuho | Initiates | Outperform | $0.00 → $51.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 20 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 48.6% below the 50-day MA ($5.33).
- bearish: Price vs 200-day MA: Trading 72.5% below the 200-day MA ($9.97).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.08) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($2.74).
UPB Price Chart
Loading chart for UPB…
Fundamentals
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.